NCT06364007View on ClinicalTrials.gov

HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

HAIC+STRIDE+Len

patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).

Trial Locations (1)

Unknown

RECRUITING

Hunan Provincial People's Hospital(The First Affiliated Hospital of Hunan Normal University), Changsha

All Listed Sponsors
lead

Sulai Liu

OTHER